哪些男性从前列腺癌筛查中获益?欧洲前列腺癌筛查随机研究中按亚组分析的前列腺癌死亡率
该回顾性队列研究基于欧洲前列腺癌筛查随机研究(ERSPC)芬兰、荷兰和瑞典三个中心126 827名55-69岁男性,随访最长16年,评估不同年龄组和EAU风险组的前列腺癌死亡率差异。结果显示筛查效果因中心和年龄组而异,筛查效应似乎取决于筛查持续时间及筛查轮次的数量和频率,死亡率降低主要归因于分期迁移。
要点
- 55-59岁组筛查臂与对照臂前列腺癌死亡HR:芬兰0.96(95%CI 0.75-1.24),荷兰0.70(95%CI 0.44-1.12),瑞典0.42(95%CI 0.24-0.73)。
- 60-64岁组HR:芬兰1.03(95%CI 0.77-1.37),荷兰0.76(95%CI 0.50-1.16),瑞典0.97(95%CI 0.64-1.48)。
- 诊断时晚期疾病男性前列腺癌死亡率显著降低:芬兰0.67(95%CI 0.56-0.82),荷兰0.28(95%CI 0.18-0.44),瑞典0.48(95%CI 0.30-0.78)。
核心结论
- 无法明确识别最佳筛查年龄组,因为死亡率降低在各中心和年龄组间存在差异。
- 筛查效应似乎取决于筛查持续时间以及筛查轮次的数量和频率。
- 筛查带来的前列腺癌死亡率降低主要归因于分期迁移。
研究设计与样本
- 回顾性队列研究,基于ERSPC芬兰、荷兰和瑞典三个中心。
- 纳入126 827名55-69岁男性,随机分组后随访最长16年。
- 主要结局为前列腺癌死亡率,分析三个年龄组(55-59、60-64、65-69岁)和四个EAU风险组(低危、中危、高危和晚期疾病)。
主要发现
- 55-59岁组筛查臂相对对照臂前列腺癌死亡HR:芬兰0.96(95%CI 0.75-1.24),荷兰0.70(95%CI 0.44-1.12),瑞典0.42(95%CI 0.24-0.73)。
- 60-64岁组HR:芬兰1.03(95%CI 0.77-1.37),荷兰0.76(95%CI 0.50-1.16),瑞典0.97(95%CI 0.64-1.48)。
- 65-69岁组HR:芬兰0.80(95%CI 0.62-1.03),荷兰0.57(95%CI 0.38-0.83),瑞典该年龄组缺失。
- 诊断时晚期疾病男性前列腺癌死亡率在三个国家均实质性降低:芬兰0.67(95%CI 0.56-0.82),荷兰0.28(95%CI 0.18-0.44),瑞典0.48(95%CI 0.30-0.78)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether a subgroup of men can be identified that would benefit more from screening than others. MATERIALS AND METHODS: This retrospective cohort study was based on three European Randomised Study of Screening for Prostate Cancer (ERSPC) centres, Finland, the Netherlands and Sweden. We identified 126 827 men aged 55-69 years in the study who were followed for maximum of 16 years after randomisation. The primary outcome was prostate cancer (PCa) mortality. We analysed three age groups 55-59, 60-64 and 65-69 years and PCa cases within four European Association of Urology (EAU) risk groups: low, intermediate, high risk, and advanced disease. RESULTS: The hazard ratio (HR) for PCa mortality in the screening arm relative to the control arm for men aged 55-59 years was 0.96 (95% confidence interval [CI] 0.75-1.24) in Finland, 0.70 (95% CI 0.44-1.12) in the Netherlands and 0.42 (95% CI 0.24-0.73) in Sweden. The HR for men aged 60-64 years was 1.03 (95% CI 0.77-1.37) in Finland, 0.76 (95% CI 0.50-1.16) in the Netherlands and 0.97 (95% CI 0.64-1.48) in Sweden. The HR for men aged 65-69 years was 0.80 (95% CI 0.62-1.03) in Finland and 0.57 (95% CI 0.38-0.83) in the Netherlands, and this age group was absent in Sweden. In the EAU risk group analysis, PCa mortality rates were materially lower for men with advanced disease at diagnosis in all three countries: 0.67 (95% CI 0.56-0.82) in Finland, 0.28 (95% CI 0.18-0.44) in the Netherlands, and 0.48 (95% CI 0.30-0.78) in Sweden. CONCLUSION: We were unable to unequivocally identify the optimal age group for screening, as mortality reduction differed among centres and age groups. Instead, the screening effect appears to depend on screening duration, and the number and frequency of screening rounds. PCa mortality reduction by screening is largely attributable to stage shift.
引用
- Pasanen N, Talala K, Remmers S, et al. Which men benefit from prostate cancer screening? Prostate cancer mortality by subgroup in the European Randomised Study of Screening for Prostate Cancer. BJU Int. 2024. PMID: 38725182. doi:10.1111/bju.16394
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。